title: 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography uptake in systemic lupus erythematosus-associated adenopathy.
abstract: Systemic lupus erythematosus (SLE) and lymphoma are disease entities that often have similar presenting signs and symptoms that can complicate or delay definitive diagnosis. 2-Deoxy-2-[(18)F]fluoro-D-glucose positron emission tomography (FDG-PET) has become a valuable tool in the diagnosis, staging, and evaluation of response to therapy in lymphoma patients. However, its utility in patients with SLE has been limited to the central nervous system. Significant FDG uptake has not been previously reported in lymphadenopathy associated with SLE. The case presented is an example of histologically proven benign adenopathy in a 16-year-old female with SLE that was hypermetabolic on FDG-PET imaging. It highlights the importance of recognizing that widespread inflammatory adenopathy in SLE can mimic the pattern of FDG uptake seen with lymphoma at PET imaging.
authors.affiliation: Department of Radiology, Internal Medicine/Rheumatology, Allergy & Immunology, and Pediatrics/Hematology and Oncology, Virginia Commonwealth University, Medical College of Virginia Campus, Richmond, VA 23298, USA.
authors.forename: Geoffrey L
authors.initials: GL
authors.lastname: Fey
authors.forename: Paul R
authors.initials: PR
authors.lastname: Jolles
authors.forename: Lenore M
authors.initials: LM
authors.lastname: Buckley
authors.forename: Gita V
authors.initials: GV
authors.lastname: Massey
mesh_terms: D000293:Adolescent; D003937:Diagnosis, Differential; D005260:Female; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008180:Lupus Erythematosus, Systemic / Q000150:complications*; D008206:Lymphatic Diseases / Q000150:complications / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D014055:Tomography, Emission-Computed
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18